XML 29 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 29, 2018
Jun. 30, 2017
Statement of Cash Flows [Abstract]    
Net income $ 203,351 $ 34,356
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 1,176 563
Stock-based compensation expense 18,588 9,740
401(k) matching contributions made in common stock 2,723 998
Loss on extinguishment of debt 0 6,239
Amortization of debt discounts and debt issuance costs 0 182
Interest paid in kind 0 (11,825)
Gain on other equity investments (209) (639)
Other (490) 148
Changes in assets and liabilities:    
Trade and other receivables (85,969) (2,581)
Inventory, net (1,714) (2,087)
Prepaid expenses and other current assets (1,577) 1,049
Other long-term assets 3 519
Accounts payable (1,535) 472
Accrued compensation and benefits 465 (4,779)
Accrued clinical trial liabilities (3,048) 549
Accrued collaboration liabilities (1,261) 5,873
Deferred revenue 5,910 28,159
Other current and long-term liabilities 10,164 7,457
Net cash provided by operating activities 146,577 74,393
Cash flows from investing activities:    
Purchases of property and equipment (15,182) (2,298)
Purchases of investments (227,012) (154,809)
Proceeds from maturities of investments 139,948 200,893
Proceeds from sale of investments 10,237 37,294
Proceeds from other equity investments 209 639
Net cash provided by (used in) investing activities (91,800) 81,719
Cash flows from financing activities:    
Repayment of convertible notes and term loan payable 0 (185,788)
Proceeds from exercise of stock options 6,550 12,980
Proceeds from employee stock purchase plan 3,650 3,053
Taxes paid related to net share settlement of equity awards (2,976) (2,331)
Principal payments on financing lease obligation (304) 0
Net cash used in financing activities 6,920 (172,086)
Net increase (decrease) in cash, cash equivalents and restricted cash 61,697 (15,974)
Cash, cash equivalents and restricted cash at beginning of period 188,314 155,836
Cash, cash equivalents and restricted cash at end of period 250,011 139,862
Supplemental cash flow disclosure - non-cash investing and financing activity:    
Property and equipment deemed to have been acquired under build-to-suit lease 6,864 14,530
Unpaid liabilities incurred to acquire Property and equipment $ 13,972 $ 531